奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎的病毒学应答情况分析

doi:10.19871/j.cnki.xfcrbzz.2023.04.011

新发传染病电子杂志 ›› 2023, Vol. 8 ›› Issue (4): 50-53.doi: 10.19871/j.cnki.xfcrbzz.2023.04.011

奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎的病毒学应答情况分析

蔡晓娟¹, 汪美华¹, 毛莉萍¹, 薛红², 缪幼菡¹, 姚超¹, 朱晓红¹

1.南通大学附属南通第三医院感染科,江苏南通 226000;
2.通大学附属南通第三医院肝病科,江苏南通 226000

收稿日期:2023-02-11 出版日期:2023-08-31 发布日期:2023-09-26
通讯作者: 朱晓红,Email：23378589@qq.com
基金资助:
南通市科技计划（指导性）项目（MSZ20172）

Analysis of virology response of obipari combined with dasepvir in the treatment of genotype 1b chronic hepatitis C

Cai Xiaojuan¹, Wang Meihua¹, Mao Liping¹, Xue Hong², Miao Youhan², Yao Chao¹, Zhu Xiaohong¹

1. Department of Infections, Nantong Third Hospital Affiliated to Nantong University, Jiangsu Nantong 226000, China;
2. Department of Hepatology, Nantong Third Hospital Affiliated to Nantong University, Jiangsu Nantong 226000, China

Received:2023-02-11 Online:2023-08-31 Published:2023-09-26

摘要/Abstract

摘要： 目的探究奥比帕利与达塞布韦联合治疗基因1b型慢性丙型肝炎患者的效果以及病毒学应答情况,以期为临床基因1b型慢性丙型肝炎治疗方案的选择提供参考。方法选取南通大学附属南通第三医院2019年1月至2022年1月的基因1b型慢性丙型肝炎患者136例作为研究对象,给予患者每日1次奥比帕利（奥比他韦/帕立瑞韦/利托那韦）25/150/100mg联合每日2次达塞布韦250mg治疗。所有患者均接受12周治疗,并随访至治疗结束后24周,分别于治疗第4周、治疗结束时、治疗结束后12周和治疗结束后24周评估患者的病毒学应答情况,并记录随访期间患者的不良反应情况。结果纳入的136例患者中,男性75例（55.15%）,女性61例（44.85%）,其中初治患者127例（93.38%）,奥比帕利或达塞布韦经治患者5例（3.68%）,干扰素经治患者4例（2.94%）;肝硬化患者10例（7.35%）。随访至治疗结束后24周时,所有患者均未出现死亡、失联情况,治疗第4周时、治疗结束时、治疗结束后12周、治疗结束后24周患者的病毒学应答率均为100%（136/136）。共发现108次轻度不良事件。未出现导致停用研究药物的不良事件和死亡事件,且发生的不良事件和异常情况判定与本研究药物无关。结论奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎,病毒学应答率为100%,且安全性较高。

关键词: 丙型肝炎, 奥比帕利, 达塞布韦, 病毒学应答, 不良反应

Abstract: Objective To explore the effect and Virology response of the combination of obipari and dasepvir in the treatment of chronic hepatitis C patients with genotype 1b, so as to provide reference for the selection of clinical treatment plans for chronic hepatitis C patients with genotype 1b. Method 136 patients with genotype 1b chronic hepatitis C in Nantong Third Hospital Affiliated to Nantong University from January 2019 to January 2022 were selected as the study subjects. Patients were treated with ombitasvir (ombitasvir/paritaprevir/ritonavir) 25/150/100mg once daily combined with dasubuvir 250 mg twice daily. All patients received a 12 week treatment regimen and were followed up for 24 weeks after the end of treatment. The virological response of the patients was evaluated at week 4, the end of treatment, 12 weeks and 24 weeks after the end of treatment, and the adverse reactions of the patients during the follow-up period were recorded. Result A total of 136 patients were enrolled, 75 were male (55.15%) and 61 were female (44.85%). Among them, 127 (93.38%) were newly diagnosed patients, 5 (3.68%) were treated with ombitasvir or dasubuvir, and 4 (2.94%) were treated with interferon. There were 10 patients (7.35%) with liver cirrhosis. All patients were followed up to 24 weeks after the end of treatment, and no death or loss of contact occurred. The virological response rate of patients was 100% (136/136) at the 4th week of treatment and 100% (136/136) at the end of treatment. The virological response rate was 100% (136/136) at 12 weeks after the end of treatment and 100% (136/136) at 24 weeks after the end of treatment. A total of 108 adverse events were reported, all of which were mild. No adverse events or deaths led to discontinuation of the study drug. Common adverse events and laboratory abnormalities that occurred were considered to be unrelated to the study drug, and no patients discontinued the study drug prematurely. Conclusion Ombitasvir combined with dasabuvir in the treatment of genotype 1b chronic hepatitis C has a virological response rate of 100% and high safety.

Key words: Hepatitis C, Obipali, Daseboure, Virological response, Adverse reactions

中图分类号:

R575.1

蔡晓娟, 汪美华, 毛莉萍, 薛红, 缪幼菡, 姚超, 朱晓红. 奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎的病毒学应答情况分析[J]. 新发传染病电子杂志, 2023, 8(4): 50-53.

Cai Xiaojuan, Wang Meihua, Mao Liping, Xue Hong, Miao Youhan, Yao Chao, Zhu Xiaohong. Analysis of virology response of obipari combined with dasepvir in the treatment of genotype 1b chronic hepatitis C[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(4): 50-53.

参考文献

[1] 刘俊平, 殷辉, 刘翠平, 等. 奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎疗效真实世界研究[J]. 中华肝脏病杂志, 2018, 26(12):927-932.
[2] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志,2015, 31(12):1961-1979.
[3] 宁会彬, 刘俊平, 肖二辉,等. 奥比帕利联合达塞布韦治疗基因1型丙型肝炎病毒感染患者的进展[J]. 中华肝脏病杂志, 2018, 26(9):710-713.
[4] HEO J, KIM YJ.Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase Ⅱ/Ⅲ Trials[J]. Gut Liver, 2021, 15(6):895-903.
[5] 庞相军, 辛桂杰. 奥比他韦/利托那韦/帕利瑞韦联合达塞布韦成功治疗再障痊愈后慢性丙型肝炎1例[J]. 现代消化及介入诊疗, 2020, 25(2):271-272.
[6] WAGNER JA, GANDHI A, JOHNSON B, et al.Hepatitis C Virus Transmission at a Long-Term Care Facility (LTCF) Providing Hemodialysis Services—Georgia, United States, 2019[J]. Infect Control Hosp Epidemiol, 2020, 41(S1):248-249.
[7] 谢志伟, 章红艳, 陆霭琪, 等. 奥比帕利联合达塞布韦治疗基因1b型慢性丙型病毒性肝炎患者的疗效与安全性分析[J]. 中华生物医学工程杂志, 2021, 27(4):380-385.
[8] 孟蕊, 芮明军, 马越,等. 治疗丙肝的第二代直接抗病毒药物的经济性系统评价[J]. 中国药房, 2020, 31(23):2882-2888.
[9] 杨永锐, 李海雯, 赵智蓉, 等. 索磷布韦维帕他韦治疗不同基因型慢性丙型肝炎患者和HCV/HIV合并感染患者的临床疗效与安全性[J]. 昆明医科大学学报, 2021, 42(7):130-136.
[10] 胡春霞, 杨娇楠, 张丰晓, 等. 格卡瑞韦/哌仑他韦治疗基因1b型慢性丙型肝炎患者疗效及安全性分析[J]. 实用肝脏病杂志, 2022, 25(3):359-362.
[11] 刘敏,曾琴,潘亮,等. 聚乙二醇干扰素α-2b联合利巴韦林治疗HIV/HCV合并感染的回顾性研究[J/CD].新发传染病电子杂志,2021,6(1):31-34.
[12] BILGEHAN A, NEE D, ORHAN Y, et al.Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience[J]. Turk J Gastroenterol, 2020, 31(4):305-317.
[13] 侯艺辉, 刘腾飞, 赵晓青, 等. 不同直接抗病毒药物方案对基因1b型慢性丙型肝炎及代偿期丙型肝炎肝硬化临床结局的影响[J]. 临床肝胆病杂志, 2020, 36(1):84-87.
[14] 韩宏艳, 潘娟, 蒋文平, 等. 3D方案治疗基因1b型低病毒载量慢性丙型肝炎患者应答疗效研究[J]. 实用肝脏病杂志, 2021, 24(5):689-692.
[15] 孙皆齐, 姜绍文, 汪铮. 应用艾尔巴韦/格拉瑞韦治疗基因1b型慢性丙型肝炎初治和经治患者效果对比研究[J]. 实用肝脏病杂志, 2022, 25(2):195-198.
[16] 王奕璇, 王建军, 闫涛, 等. 直接抗病毒药物治疗基因1b型慢性丙型肝炎病毒感染的真实世界临床研究[J]. 军事医学, 2020, 7:534-540.
[17] 李晓月,李述捷,易永祥. 乙型肝炎病毒和丙型肝炎病毒相关性肝癌的研究进展[J/CD].新发传染病电子杂志,2022, 7(1):92-99.
[18] 符垂师, 张杰伟. α干扰素联合利巴韦林治疗儿童丙型肝炎患者病毒学应答率分析[J]. 实用肝脏病杂志, 2020, 23(3):344-347.
[19] 揭育胜, 袁静, 张晓红, 等. 奥比帕利联合达塞布韦用于中国基因1b型丙型肝炎病毒慢性感染的真实世界研究[J]. 中华肝脏病杂志, 2019, 27(2):123-127.
[20] 金巧菲, 杨国华, 周毅骏, 等. 索磷布韦联合达拉他韦治疗初治1b型慢性丙型肝炎患者临床疗效及安全性分析[J]. 中华全科医师杂志, 2020, 19(11):1043-1047.

奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎的病毒学应答情况分析

Analysis of virology response of obipari combined with dasepvir in the treatment of genotype 1b chronic hepatitis C

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

本文评价

[1]	李剑, 杨梁梓, 刘智, 吴芃瑶, 邱露露, 傅佳鹏, 柯学, 高文英, 李国保. 抗结核固定剂量复合制剂导致急性肾功能损伤1例报道[J]. 新发传染病电子杂志, 2023, 8(3): 64-67.
[2]	韦玉素, 董文逸, 谢志满, 韦黎娟. 艾滋病抗病毒治疗药物不良反应研究进展[J]. 新发传染病电子杂志, 2023, 8(3): 79-83.
[3]	付寒, 王鹏, 张宗华, 季乐财. 标准抗结核治疗方案对耐多药肺结核患者肾功能的影响分析[J]. 新发传染病电子杂志, 2022, 7(3): 32-36.
[4]	李晓月, 李述捷, 易永祥. 乙型肝炎病毒和丙型肝炎病毒相关性肝细胞癌的研究进展[J]. 新发传染病电子杂志, 2022, 7(1): 92-99.
[5]	刘敏, 曾琴, 潘亮, 张辉芬, 霍琴, 陈耀凯. 聚乙二醇干扰素α-2b联合利巴韦林治疗HIV/HCV合并感染的回顾性研究[J]. 新发传染病电子杂志, 2021, 6(1): 31-34.
[6]	季乐财, 余卫业, 谭卫国, 吕德良, 吕建文. 利奈唑胺治疗重症耐多药肺结核临床观察及不良反应分析[J]. 新发传染病电子杂志, 2019, 4(4): 217-219.
[7]	赵方, 李巍, 郑祎, 刘晓宁, 周泱, 张路坤, 彭巧丽, 王辉, 何云. 艾滋病抗病毒治疗患者依非韦伦血药浓度及相关因素的分析[J]. 新发传染病电子杂志, 2019, 4(2): 103-107.
[8]	付小义, 金娴, 徐晓婧, 彭雁忠. 泛基因型DAA治疗慢性丙型肝炎[J]. 新发传染病电子杂志, 2018, 3(1): 30-33.
[9]	苏冬娜, 吴诗品. 慢性丙型病毒性肝炎患者PBMC中2-5AS的表达及其与Stat1和Stat2水平相关性分析[J]. 新发传染病电子杂志, 2017, 2(2): 81-84.